PRL3 induces polypoid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse

Abstract

Thura and colleagues report that PRL3 promotes PGCCs, which are found to be enriched in relapsed tumours. The authors demonstrated that this relapse can be prevented using PRL3-zumab for use in adjuvant immunotherapy to target PRL3-expressing PGCCs, thus preventing metastasis and relapse.